AtaCor Subcostal Temporary Extravascular Pacing III Study (STEP III)

Third in-human study for the AtaCor Extravascular (EV) Temporary Pacing Lead System to collect initial safety and performance data for the latest AtaCor System.

The objective of the study is to generate safety and performance data of the latest AtaCor EV Temporary Pacing Lead System 1) to support the development a future pivotal study with an indication limited to a maximum of 7 days, and 2) to obtain early clinical data for future research related to longer-term use.

Study Overview

• Status: Completed
• Conditions: Conduction Defect
• Intervention / Treatment: Device: AtaCor StealthTrac Lead

Detailed Description

Prior revisions of the study intended to evaluate multiple StealthTrac Leads (Models AC-1010, AC-1020, AC-2021 and AC-1030) to support the development of a future pivotal study. In the most recent revision of the study, an additional StealthTrac Lead (Model AC-1012) will be evaluated to support use in a larger pivotal study.

This study is a feasibility study serving dual purposes: 1) to generate developmental clinical data in support of a subsequent pivotal clinical study and marketing application for temporary pacing (in patients that retain the lead for a maximum of 7 days); and 2) to obtain early data for future research related to longer-term use (in patients that retain the lead for a maximum of 14 days).

Subjects undergoing a qualifying index procedure will have a Model AC-1012 StealthTrac Lead inserted, evaluated for a Maximum Lead Insertion Time prior to removal and a final post-removal follow-up 27-33 days after lead insertion. The following elements will change after the absence of AtaCor-related cardiac tamponade and no more than one (1) serious AtaCor-related pericardial effusion has been confirmed from the initial eight (8) experiences with the Model AC-1012 StealthTrac Lead, including insertion and removal procedures performed by multiple operators:

• Maximum Lead Insertion Time will change from 7 to 14 Days
• Follow-up will change from in-hospital follow-up only to allowing hospital discharge with the StealthTrac lead inserted, but capped and inactive after Day 2 provided in-person wound checks occur at least every 3 days
• Echocardiography requirements will transition from 3 distinct days to procedure day and removal day only.

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Czechia
  • Prague, Czechia
    • Na Homolce Hospital
• New Zealand
  • Christchurch, New Zealand
    • Christchurch Hospital
  • Wellington, New Zealand
    • Wellington Regional Hospital
• Paraguay
  • Asunción, Paraguay
    • Sanatorio Italiano

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. At least 18 years old
2. Indicated for closed-chest cardiac invasive procedure (e.g. transcatheter valve replacement, balloon valvuloplasty, permanent pacemaker implantation and pacing lead extractions/revisions)

Exclusion Criteria:

1. NYHA IV functional class
2. Oxygen dependency
3. BMI ≥ 35 kg/m2
4. Circumstances that prevent data collection or follow-up (e.g., inability to perform a short walk with the Holter monitor)
5. Participation in any concurrent clinical study without prior written approval from the Sponsor

6. Inability to give an informed consent to participate in the Study

   Known prior history for any of the following:

7. Median or partial sternotomy
8. Surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium
9. Significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
10. Thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV Temporary Pacing Lead System insertion procedure
11. Pericardial disease, pericarditis and mediastinitis
12. Medical treatments, surgeries or conditions that increase the potential for pericardial adhesions
13. Severe to very severe airflow limitation, defined as FEV1/FVC <0.7 AND FEV1 < 50% predicted

14. Symptomatic COPD exacerbation associated with either:

    1. Modified MRC Dyspnea Scale Grade ≥2, OR
    2. CAT Assessment
15. Surgically corrected congenital heart disease (not including catheter-based procedures)
16. Allergies to the device materials such as stainless steel, titanium, platinum, iridium, polyethylene, polyurethane, polycarbonate and silicone

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AtaCor StealthTrac Lead Model AC-1010; Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010. This was the first model evaluated in the study.	Device: AtaCor StealthTrac Lead; Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
Active Comparator: AtaCor StealthTrac Lead Model AC-1020; Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020. This was the second model evaluated in the study.	Device: AtaCor StealthTrac Lead; Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
Active Comparator: AtaCor StealthTrac Lead Model AC-1021; Subjects inserted with the AtaCor StealthTrac Lead Model AC-1021. This was the third model evaluated in the study.	Device: AtaCor StealthTrac Lead; Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
Active Comparator: AtaCor StealthTrac Lead Model AC-1012; Subjects inserted with the AtaCor StealthTrac Lead Model AC-1012. This is the fourth model currently being evaluated in the study.	Device: AtaCor StealthTrac Lead; Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety - Freedom from Adverse Device Effects	Freedom from Adverse Device Effects (ADE)	Lead removal (up to 14 Days)
Performance - Pacing Capture Threshold	Summary statistics for pacing capture threshold for each StealthTrac Lead model from insertion through removal	Lead removal (up to 14 Days)
Performance - Pacing Impedance	Summary statistics for pacing impedance for each StealthTrac Lead model from insertion through removal for each StealthTrac Lead model from insertion through removal	Lead removal (up to 14 Days)
Performance - Sensed R-wave Amplitude	Summary statistics for sensed R-wave amplitude for each StealthTrac Lead model from insertion through removal	Lead removal (up to 14 Days)

Collaborators and Investigators

• Sponsor: AtaCor Medical, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): October 3, 2020
• Primary Completion (Actual): January 25, 2022
• Study Completion (Actual): May 11, 2022

Study Registration Dates

• First Submitted: August 25, 2020
• First Submitted That Met QC Criteria: August 28, 2020
• First Posted (Actual): September 4, 2020

Study Record Updates

• Last Update Posted (Actual): July 7, 2022
• Last Update Submitted That Met QC Criteria: July 5, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Temporary Ventricular Pacing
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease
• Other Study ID Numbers: DOC-10092

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes